Bone Graft Substitute
ABOUT US
NanoBone Story
®
The inventor of NanoBone, Prof. Dr. Thomas Gerber, former chair of Nanostructured Materials at the University of Rostock Institute for Physics in Germany, is a foremost nanotechnology expert in the field of the biology of bone graft substitutes.
Paul Byerley and James Cassidy, Ph.D., formed Artoss, Inc. in 2015 to commercialize NanoBone in North America. Following its first FDA clearance, NanoBone commercialization began in the U.S. in 2016. Since its launch, there has been significant market adoption and growth of NanoBone with use in over 100,000 cases in multiple orthopaedic specialties in the U.S. and EU.
Board of Directors
Paul Byerley
Chief Executive Officer
Paul has over 30 years of sales and distribution experience in startup and early-stage biologics and medical device companies in the U.S. Prior to co-founding Artoss, Inc., Paul served as Vice President of Sales for Benvenue Medical, Baxter Biosurgery, ApaTech, and Interpore Cross. At Baxter, Paul was Vice President of Orthobiologics, responsible for Actifuse sales throughout the U.S. Paul has a bachelor’s degree in Molecular Biology from California State University, Northridge.
James J. Cassidy, Ph.D.
COO and President
Jim has over 30 years of accomplishment in the medical device industry as CEO of successful companies like Electromed (NYSE:ELMD), CERAbio, and Cartificial A/S. Prior to co-founding Artoss, Inc., he served as COO at ApaTech, Vertebral Technologies, and KMI. Earlier in his career, Jim served with Collagen Corporation and Smith & Nephew. Jim has significant experience in orthobiologics business and product development. Jim has a doctorate in Biomedical Engineering from Case Western Reserve University.
Charles Emley
Charlie has over 30 years leading IT and management consulting companies. He served as Corporate Officer, Partner, and Managing Principal for Unisys, IBM, Deloitte, and E. I. DuPont and as Deputy Assistant Secretary U.S. Department of Interior and Executive Office of the President. Charlie is currently a Senior Advisor to AngelMD, a physician investor group, and heads their Catalyst I investment fund. He has an MBA from the Wharton School at the University of Pennsylvania and a BS from Lehigh University, and was a Captain in the U. S. Army.
Eugene Champeau
Gene is a med tech entrepreneur and executive with over 30 years of experience in implantable and interventional devices. Gene was CEO/founder of NeoMetrics, commercializing specialty guidewires for interventional procedures, which was acquired by Heraeus Medical Components. Prior to that, Gene served as VP of Sales and Marketing at MicroNet, FlexMedics, and Enpath. Gene has his MS from Cardinal Stritch University and his BA from St. Olaf College in Minnesota.
Gilbert Ortega
MD. MPH
Gil Ortega is co-director of the largest orthopaedic trauma fellowship program in the U.S. He is vice chair of surgery at HonorHealth Osborn and a professor at the Mayo Clinic College of Medicine and the University of Arizona College of Medicine. His specialized trauma training was at Parkland Hospital in Dallas, TX, the Trauma Center in Hannover and the Universitätsklinikum des Saarlandes Klinik in Homburg, Germany. Gil received his BS from the University of Houston, MPH and MD from Yale University. He completed this residency in orthopaedic surgery at Harvard Medical School.
Management Team
Paul Byerley
Chief Executive Officer
Paul has over 30 years of sales and distribution experience in startup and early-stage biologics and medical device companies in the U.S. Prior to co-founding Artoss, Inc., Paul served as Vice President of Sales for Benvenue Medical, Baxter Biosurgery, ApaTech, and Interpore Cross. At ApaTech, Paul was Vice President of Orthobiologics, responsible for Actifuse sales throughout the U.S. Paul has a bachelor’s degree in Molecular Biology from California State University, Northridge.
James J. Cassidy, Ph.D.
COO and President
Jim has over 30 years of accomplishment in the medical device industry as CEO of successful companies like Electromed (NYSE:ELMD), CERAbio, and Cartificial A/S. Prior to co-founding Artoss, Inc., he served as COO at ApaTech, Vertebral Technologies, and KMI. Earlier in his career, Jim served with Collagen Corporation and Smith & Nephew. Jim has significant experience in orthobiologics business and product development. Jim has a doctorate in Biomedical Engineering from Case Western Reserve University.
Ryan O’Neill
Area Vice President of Sales - Central
Ryan Has over 20 years of medical device and orthopaedic-related sales and commercial experience. Ryan started at Artoss, Inc. in October 2017 and serves as the Area VP of Sales for the Central and SE U.S. Prior to his current role, Ryan was Director of Distribution East at AxoGen, managing multiple distributorships and growing commercial presence. In addition, he has significant experience in clinical and technical sales management. Ryan has a BA from Winona State University in Winona, MN.
Billy Lapp
Area Vice President of Sales – East
Billy has over 17 years of medical device experience in orthopaedic and biotech sales and commercialization. Billy started at Artoss, Inc. in September 2018 and serves as the Area VP of Sales for the Eastern U.S. Prior to his current role, Billy held regional account management positions at LifeNet and Stryker, managing significant territory growth. Billy has a BS from Towson University in Towson, Maryland.
Douglas Eayrs
Financial Controller
Douglas has over fifteen years of medical device experience serving in CFO or Controller positions. Previously he worked as a securities analyst providing research coverage of numerous publicly traded medical device and biotech companies for regional brokerage firms. Douglas started at Artoss Inc. in September 2019 as the financial controller. He has a Masters Degree in Applied Economics from Marquette University in Milwaukee Wisconsin. He is a Chartered Financial Analyst (“CFA”) and is a member of the CFA Institute, a worldwide professional association of investment professionals.
News & Events
PRESS RELEASES
Janurary 9, 2022 Artoss, Inc. Announces Record 2021 Revenue for NanoBone® Bone Graft Substitute »
May 26, 2021 Artoss, Inc. Recruits 100 Patients in Key Clinical Study on NanoBone® Bone Graft in Spinal Fusion »
NEWS
FDA.gov May 25, 2021
MedTech Outlook May 10, 2021
Vumedi Apr. 7, 2021
Backfilling ACL BTB Harvest Site Defects: How I Use NanoBiology to Bone Graft by Sean McMillan, DO »
OrthoSpine News Oct. 5, 2020
Artoss Announces Record Sales of NanoBone »
EVENTS
Note on Conferences: Meeting with our customers face-to-face is an important part of our business. However, we’re curtailing travel due to Covid-19. We remain committed to providing you the best possible opportunities to get to know our products and team. We appreciate your interest and welcome your comments and questions about NanoBone products.
American Academy of Orthopaedic Surgeons (AAOS)
Aug. 31-Sept. 3, 2021, San Diego, CA
American Orthopaedic Foot & Ankle Society (AOFAS)
September 22-25, 2021, Vancouver, Canada
North American Spine Society (NASS)
Sept. 29-Oct. 2, 2021, Boston, MA
Musculoskeletal Tumor Society (MSTS)
October 6-8, 2021, Baltimore, MD
Orthopaedic Trauma Association (OTA)
October 20-23, 2021, Fort Worth, TX